Ceftolozane-tazobactam in combination with fosfomycin for treatment of MDR/XDR P. aeruginosa infective endocarditis

Ceftolozane-tazobactam in combination with fosfomycin for treatment of MDR/XDR P. aeruginosa infective endocarditis

Background: Infective endocarditis (IE) due to multi-drug (MDR) and extensively drug-resistant (XDR) Pseudomonas aeruginosa is rare. MDR P. aeruginosa infections are increasingly reported worldwide, and the choice of effective antimicrobials is limited. Ceftolozane-tazobactam is a new antimicrobial...

Full description

Bibliographic Details
Main Authors: A. Prescott, S. Kennedy, P. Howard, T. Collyns, M.H. Gilleece, F. Pirone, M.W. Baig, C. Donnellan, J.A.T. Sandoe
Format: Article
Language:English
Published: Elsevier 2019-10-01
Series:Clinical Infection in Practice
Subjects:
Ceftolozane-tazobactam
Multi-drug resistant
Extensively drug resistant
Pseudomonas aeruginosa
Infective endocarditis
Intravascular catheter-related bloodstream infection
Online Access:http://www.sciencedirect.com/science/article/pii/S2590170219300111

Internet

http://www.sciencedirect.com/science/article/pii/S2590170219300111

Similar Items